Key result
Periprocedural MI rates differed markedly by definition (1.6% by WHO vs 7.8% by Universal/ARC criteria), but neither definition was associated with mortality up to 2 years.
Why the study?
Does the definition of periprocedural MI (WHO vs Universal/ARC) affect the reported incidence and its association with 2-year mortality in patients with stable CAD undergoing stenting?
RCT (n=3,687)
Does the definition of periprocedural MI (WHO vs Universal/ARC) affect the reported incidence and its association with 2-year mortality in patients with stable CAD undergoing stenting?
The incidence of periprocedural MI varies significantly depending on the definition used, but neither definition was associated with increased 2-year mortality.
No takes yet. Share an insight, caveat, or question.
Neither periprocedural MI definition predicts 2-year mortality after stenting; challenges reliance on this endpoint for prognostic assessment in stable CAD trials.
Pervaiz et al. (2012) conducted an RCT in stable coronary artery disease (n=3,687). Everolimus-eluting stents vs. Paclitaxel-eluting stents was evaluated on Periprocedural myocardial infarction within 48 hours post index procedure. Periprocedural MI rates differed markedly by definition (1.6% by WHO vs 7.8% by Universal/ARC criteria), but neither definition was associated with mortality up to 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: